These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25247332)

  • 1. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.
    van Gelder T; van Schaik RH; Hesselink DA
    Nat Rev Nephrol; 2014 Dec; 10(12):725-31. PubMed ID: 25247332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation.
    Thervet E; Anglicheau D; Legendre C; Beaune P
    Ther Drug Monit; 2008 Apr; 30(2):143-50. PubMed ID: 18367973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.
    Zhao W; Fakhoury M; Jacqz-Aigrain E
    Ther Drug Monit; 2010 Dec; 32(6):688-99. PubMed ID: 21068645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological surrogates of allograft outcome.
    Mahalati K; Kahan BD
    Ann Transplant; 2000; 5(2):14-23. PubMed ID: 11217202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients.
    Golubovic B; Prostran M; Miljkovic B; Vucicevic K; Radivojevic D; Grabnar I
    Curr Med Chem; 2016; 23(19):1998-2011. PubMed ID: 26687831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 7. Practicability of pharmacogenetics in transplantation medicine.
    van Gelder T; van Schaik RH; Hesselink DA
    Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genes and beans: pharmacogenomics of renal transplant.
    Murray B; Hawes E; Lee RA; Watson R; Roederer MW
    Pharmacogenomics; 2013 May; 14(7):783-98. PubMed ID: 23651025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of immunosuppressive agents for solid organ transplantation in children.
    Coelho T; Tredger M; Dhawan A
    Pediatr Transplant; 2012 Mar; 16(2):106-22. PubMed ID: 22360399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences.
    Dirks NL; Huth B; Yates CR; Meibohm B
    Int J Clin Pharmacol Ther; 2004 Dec; 42(12):701-18. PubMed ID: 15624287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Applied pharmacogenetic].
    Thervet É
    Nephrol Ther; 2016 Apr; 12 Suppl 1():S99-S103. PubMed ID: 26972091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Junghanss C; Rathsack S; Wacke R; Weirich V; Vogel H; Drewelow B; Mueller S; Altmann S; Freund M; Lange S
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1061-8. PubMed ID: 22182476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.
    Provenzani A; Santeusanio A; Mathis E; Notarbartolo M; Labbozzetta M; Poma P; Provenzani A; Polidori C; Vizzini G; Polidori P; D'Alessandro N
    World J Gastroenterol; 2013 Dec; 19(48):9156-73. PubMed ID: 24409044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials.
    Sánchez-Fructuoso AI
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):807-19. PubMed ID: 18611120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of mycophenolic acid and kidney function during combined immunosuppressive therapy.
    Oláh AV; Asztalos L; Ivády G; Varga E; Kovács AM; Kappelmayer J; Varga J
    Clin Chem Lab Med; 2011 Nov; 49(11):1849-53. PubMed ID: 21848499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring.
    Holt DW; Armstrong VW; Griesmacher A; Morris RG; Napoli KL; Shaw LM; ; ;
    Ther Drug Monit; 2002 Feb; 24(1):59-67. PubMed ID: 11805724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.